Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

Company's belief that the supplemental data to be submitted in the amended NDA will overcome the need for additional trials, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drugs Advisory Committee that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for L- MTP-PE, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Ph
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
(Date:7/29/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader in product ... align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and the ... of an accurate label, and pictogram uses and meanings. , “With changes to ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company, is pleased to announce that ... injector (RCI-02) have been locked.  Prototypes for industrial ... prepare for an application for CE mark clearance ... in 2016. (Photo: ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... Inc. (Nasdaq: BCRX ) today announced Thomas ... and interim Chief Medical Officer. Dr.,Simon brings more ... to his position at BioCryst., (Logo: ... to have Tom join BioCryst at this important ...
... and Newport News, Va. Also ... Recognized, ... and remarkable achievements in its,community, Harborview Medical Center of Seattle is the ... the most esteemed,honors of excellence in community service in healthcare. As one ...
... life sciences industry faces a host of policy ... and nationally, SAN FRANCISCO, Jan. 10 ... providing a broad overview of,the productivity of Northern ... science research cluster in the world. To ensure,continued ...
Cached Biology Technology:BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6Bioscience Group Warns Policymakers Against Complacency 2Bioscience Group Warns Policymakers Against Complacency 3
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... 2013)There are over a million people with spinal cord injuries ... new cases every year. Furthermore, it is estimated that there ... the largest integrated health care system in the world for ... discovering all the various ways that SCI affect those with ...
... may provide greater climatic and economic benefits than if ... a Dartmouth College study that for the first time ... the sun,s energy. The findings suggest more frequent ... pocketbooks in high latitude areas where snowfall is common ...
... 2013) A new method to identify previously hidden ... process of novel drug design, according to scientists at ... and experimental data helped Rice theorists predict intermediate configurations ... detect. The work should be significant for ...
Cached Biology News:Quadriplegics at risk for serious sleep breathing disorder 2Quadriplegics at risk for serious sleep breathing disorder 3More logging, deforestation may better serve climate in some areas 2Proteins' passing phases revealed 2Proteins' passing phases revealed 3
... protein sample is a complex protein ... pattern when used with ReadyPrep 2-D ... This sample can be used as ... system and protocol before using more ...
... Tecans new HydroFlex platform provides ... a range of 96-well format applications, ... and protein arrays, and vacuum filtration-to-waste, ... platforms outstanding on-line control features set ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
... raised against a partial recombinant ... ZFHX4 (NP_078997, 2 a.a. ... protein with GST tag. ... NM_024721 Protein ...
Biology Products: